title: Bmi-1 is useful as a novel molecular marker for predicting progression of myelodysplastic syndrome and patient prognosis.
abstract: The International Prognostic Scoring System (IPSS) has been widely used to predict the prognosis of patients with myelodysplastic syndrome (MDS). However, IPSS does not always provide a sufficiently precise evaluation of patients to allow the appropriate choice of clinical interventions. Here, we analyzed the expression of Bmi-1, which is required to regulate the self-renewal in CD34+ cells from 51 patients with cases of MDS and acute myeloid leukemia preceded by MDS (MDS-AML). Higher positivity rate of Bmi-1 was preferentially seen in refractory anemia with excess blasts (RAEB), RAEB in transformation (RAEB-T), and MDS-AML compared with refractory anemia (RA) and RA with ringed sideroblasts (RARS). IPSS score was positively correlated with the percentage of Bmi-1 expression. Patients with RA and RARS with a higher percentage of Bmi-1+ cells showed disease progression to RAEB. Here, we propose Bmi-1 as a novel molecular marker to predict the progression and prognosis of MDS.
authors.affiliation: Department of Hematology and Oncology, Research Institute for Radiation Biology and Medicine, Hiroshima University, 1-2-3 Kasumi, Minami-ku, Hiroshima, Japan 734-8553. kmmihara@hiroshima-u.ac.jp
authors.forename: Keichiro
authors.initials: K
authors.lastname: Mihara
authors.forename: Moniruddin
authors.initials: M
authors.lastname: Chowdhury
authors.forename: Nanae
authors.initials: N
authors.lastname: Nakaju
authors.forename: Sachiko
authors.initials: S
authors.lastname: Hidani
authors.forename: Akihiro
authors.initials: A
authors.lastname: Ihara
authors.forename: Hideo
authors.initials: H
authors.lastname: Hyodo
authors.forename: Shin'ichiro
authors.initials: S
authors.lastname: Yasunaga
authors.forename: Yoshihiro
authors.initials: Y
authors.lastname: Takihara
authors.forename: Akiro
authors.initials: A
authors.lastname: Kimura
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D000753:Anemia, Refractory / Q000175:diagnosis; D018952:Antigens, CD34; D015415:Biomarkers / Q000032:analysis; D001853:Bone Marrow / Q000737:chemistry / Q000473:pathology; D016022:Case-Control Studies; D049109:Cell Proliferation; D018450:Disease Progression; D005260:Female; D006801:Humans; D007951:Leukemia, Myeloid; D008297:Male; D008875:Middle Aged; D009190:Myelodysplastic Syndromes / Q000175:diagnosis* / Q000473:pathology; D009687:Nuclear Proteins / Q000032:analysis*; D063150:Polycomb Repressive Complex 1; D011379:Prognosis; D011518:Proto-Oncogene Proteins / Q000032:analysis*; D012097:Repressor Proteins / Q000032:analysis*
chemical_list: D018952:Antigens, CD34; C069077:BMI1 protein, human; D015415:Biomarkers; D009687:Nuclear Proteins; D011518:Proto-Oncogene Proteins; D012097:Repressor Proteins; D063150:Polycomb Repressive Complex 1